Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Medication Guide News

Page 21 - Medication Guide News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Medication Guide. Real-time updates on events, politics, business and more.

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

May 25, 2023
After four years of follow-up, KEYTRUDA plus LENVIMA reduced the risk of death by 21% versus sunitinib in the pivotal Phase 3 CLEAR /KEYNOTE-581 trial Final results will be presented at ASCO 2023... | May 25, 2023
New Zealand United States Thomas Hutson Corina Dutcus Gregory Lubiniecki Urologic Cancer Research
Source: marketscreener.com

Genmab A/S: Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

May 25, 2023
Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide (R2) in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma
United States New Jersey David Freundel Judith Klimovsky Andrew Carlsen Gewinn Nur
Source: finanznachrichten.de

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

May 25, 2023
Media ReleaseCOPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide in high-risk follicular lymphomaPoster presentations... | May 25, 2023
United States New Jersey Judith Klimovsky David Freundel Andrew Carlsen Kalvebod Brygge
Source: marketscreener.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

May 25, 2023
25.05.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced data from the final pre-specified overall survival (OS) analysis of the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial investigating KEYTRUDA, ...
United States New Zealand Gregory Lubiniecki Corina Dutcus Thomas Hutson Global Clinical Development
Source: wallstreet-online.de

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

May 25, 2023
Oral presentations will highlight epcoritamab-bysp in combination with rituximab-lenalidomide in high-risk follicular lymphoma Poster presentations will highlight epcoritamab in lymphoma across... | June 11, 2023
United States New Jersey Judith Klimovsky European Hematology Association International Conference On Malignant Lymphoma European Medicines Agency
Source: marketscreener.com

Corium's Novel ADHD Medication AZSTARYS® (Serdexmethylphenidate and Dexmethylphenidate) Had No Clinically Significant Impact on Children's Weight and Height Growth Rate

May 22, 2023
/PRNewswire/ -- Corium, LLC, a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS)...
United States Ann Childress Adolesc Psychopharmacol Us Centers For Disease Prnewswire Corium Adolescent Psychopharmacology
Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science